Q3 2025 · 13F-HR
NEA Management Company, LLCholdings as filed
Filed 2025-11-14 · accession 0000897069-25-001705
$1.82B
Reported value
29
Positions
2025-09-30
Period end
The Brief · NEA Management Company, LLC · Q3 2025
AI · grounded in 13F
NEA Management Company, LLC established a new position in Rhythm Pharmaceuticals Inc RYTM valued at $293.9M. The fund also initiated new stakes in Arcellx Inc ACLXGBX for $250M and Verona Pharma PLC VRNA for $240.4M. Additional new positions include Coursera Inc COUR at $150.7M and Trevi Therapeutics Inc TRVI at $121M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $293.9M | 16.1% | 2,909,956 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $250.0M | 13.7% | 3,045,262 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $240.4M | 13.2% | 2,252,994 | Common | SOLE |
| 22266M104 | COUR | COURSERA INC | $150.7M | 8.27% | 12,867,769 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $121.0M | 6.64% | 13,222,228 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $105.9M | 5.81% | 2,144,261 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $87.4M | 4.79% | 24,471,264 | Common | SOLE |
| H17182108 | CRSP | CRISPR THERAPEUTICS AG | $68.6M | 3.76% | 1,058,570 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $63.3M | 3.47% | 3,614,486 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $60.7M | 3.33% | 2,733,719 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $57.0M | 3.13% | 7,692,298 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $52.2M | 2.87% | 1,090,793 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $49.4M | 2.71% | 4,118,621 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $47.6M | 2.61% | 18,093,034 | Common | SOLE |
| 05156V102 | AUPH | AURINIA PHARMACEUTICALS INC | $43.9M | 2.41% | 3,969,834 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $23.1M | 1.27% | 1,960,169 | Common | SOLE |
| 10920V404 | — | NEUEHEALTH INC | $18.2M | 1.00% | 2,726,917 | Common | SOLE |
| 09203E105 | BDTX | BLACK DIAMOND THERAPEUTICS I | $16.9M | 0.93% | 4,448,757 | Common | SOLE |
| 126638105 | CVRX | CVRX INC | $16.4M | 0.90% | 2,026,083 | Common | SOLE |
| 15870P307 | CSBR | CHAMPIONS ONCOLOGY INC | $11.1M | 0.61% | 1,713,720 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA | $8.3M | 0.46% | 1,462,586 | Common | SOLE |
| 68170A108 | OMDA | OMADA HEALTH INC | $8.1M | 0.44% | 364,115 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $7.6M | 0.42% | 2,233,743 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $7.4M | 0.41% | 3,568,781 | Common | SOLE |
| 81726A209 | — | SENTI BIOSCIENCES INC | $5.3M | 0.29% | 3,775,615 | Common | SOLE |
| 87166L209 | SYBX | SYNLOGIC INC | $4.9M | 0.27% | 2,922,772 | Common | SOLE |
| 57055L206 | MRKR | MARKER THERAPEUTICS INC | $1.5M | 0.08% | 1,625,678 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $1.3M | 0.07% | 478,548 | Common | SOLE |
| 45175G207 | IMA | IMAGENEBIO INC | $407,541 | 0.02% | 50,005 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.